News
AEON
0.9230
-3.32%
-0.0317
Weekly Report: what happened at AEON last week (0420-0424)?
Weekly Report · 4d ago
AEON Biopharma Sets Annual Shareholder Meeting
Barchart · 6d ago
Weekly Report: what happened at AEON last week (0413-0417)?
Weekly Report · 04/20 10:04
Weekly Report: what happened at AEON last week (0406-0410)?
Weekly Report · 04/13 10:07
Weekly Report: what happened at AEON last week (0330-0403)?
Weekly Report · 04/06 10:08
Aeon receives additional notice related to NYSE American listing standards
TipRanks · 04/06 01:20
AEON Biopharma Receives Additional NYSE American Noncompliance Notice
TipRanks · 04/03 20:37
AEON Biopharma receives additional NYSE American non-compliance notice
Seeking Alpha · 04/03 20:10
*AEON Biopharma: Company Is Not in Compliance With an Additional Continued Listing Standard >AEON
Dow Jones · 04/03 20:08
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
Barchart · 04/03 15:10
AEON Posts Net Loss In FY25; Plans To Request BPD Type 2b Meeting For ABP-450 In 2026; Stock Down
NASDAQ · 03/31 10:06
AEON Biopharma Q4 EPS $(3.72)
Benzinga · 03/30 20:34
AEON Biopharma GAAP EPS of -$3.95
Seeking Alpha · 03/30 20:17
Press Release: AEON Biopharma Reports Full Year -2-
Dow Jones · 03/30 20:05
Press Release: AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
Dow Jones · 03/30 20:05
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
Barchart · 03/30 15:05
Weekly Report: what happened at AEON last week (0323-0327)?
Weekly Report · 03/30 10:08
AEON Announces FDA Feedback On ABP-450 Biosimilar Development Following BPD Type 2a Meeting
NASDAQ · 03/26 08:11
Aeon Biopharma announces FDA feedback after Type 2a meeting
TipRanks · 03/25 12:17
AEON Biopharma Announces Feedback From FDA Following Biosimilar BPD Type 2a Meeting; Co Plans To Request BPD Type 2b Meeting With FDA In 2026 To Discuss Development Of ABP-450 As Biosimilar To BOTOX
Benzinga · 03/25 12:06
More
Webull provides a variety of real-time AEON stock news. You can receive the latest news about Aeon Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About AEON
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.